STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022Strategic Collaboration and License Agreement • March 13th, 2024 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of December 7, 2022 (the “Execution Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of the Commonwealth of Massachusetts (“Vertex”), and Entrada Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND AFFINIA THERAPEUTICS INC.Strategic Collaboration and License Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of April 14, 2020 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”), and Affinia Therapeutics Inc., a corporation organized under the laws of Delaware with a place of business at 100 Beaver Street, Waltham, MA 02453 (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
EXHIBIT 10.24 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. STRATEGIC COLLABORATION AND LICENSE AGREEMENT This Strategic Collaboration and License Agreement (the...Strategic Collaboration and License Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FIRST AMENDMENT TO STRATEGIC COLLABORATION...Strategic Collaboration and License Agreement • May 13th, 2022 • EQRx, Inc. • Pharmaceutical preparations • New York
AGREEMENT (“First Amendment”) effective as of December 14, 2021 (“First Amendment Effective Date”) by and among HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation incorporated under the laws of China having its principal place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh Healthtech”) and JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD., a corporation incorporated under the laws of China having its principal place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyuangang, Jiangsu, China (“Jiangsu Hansoh” and together with Hansoh Healthtech, “Hansoh”), and EQRX, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02139, United States (“EQRx”). Hansoh and EQRx are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • May 5th, 2015 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Second Amended and Restated Strategic Collaboration and License Agreement (the “Agreement”) is executed this January 8, 2015 (the “Second Restatement Date”), between Isis Pharmaceuticals, Inc., a Delaware corporation having an address at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (“Alnylam”). Isis and Alnylam may be referred to herein as the “Parties,” or each individually as a “Party.”
STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • May 30th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
STRATEGIC COLLABORATION AND LICENSE AGREEMENT Between MODERNATX, INC. and METAGENOMI, INC. October 29, 2021Strategic Collaboration and License Agreement • January 5th, 2024 • Metagenomi Technologies, LLC • Biological products, (no disgnostic substances) • New York
This STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 29, 2021 (the “Effective Date”) by and between METAGENOMI, INC., a company incorporated under the laws of Delaware having an address at 1545 Park Ave, Emeryville, CA 94608 (“Metagenomi”), and MODERNATX, INC., a corporation organized and existing under the laws of Delaware, with its principal business office located at 200 Technology Square, Cambridge, MA 02139 (“Moderna”). Moderna and Metagenomi are each hereafter referred to individually as a “Party” and together as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • August 7th, 2009 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Strategic Collaboration and License Agreement (the “Agreement”) is executed this April 28, 2009 (the “Restatement Date”), between Isis Pharmaceuticals, Inc., a Delaware corporation having an address at 1896 Rutherford Road, Carlsbad, CA 92008 (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, Cambridge, MA 02142 (together with its wholly owned subsidiaries Alnylam U.S., Inc., a Delaware corporation, and Alnylam Europe AG, a company organized under the laws of Germany, “Alnylam”). Isis and Alnylam may be referred to herein as the “Parties,” or each individually as a “Party.”
AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • August 6th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Amended and Restated Strategic Collaboration and License Agreement (the “Agreement”) is executed this April 28, 2009 (the “Restatement Date”), between ISIS PHARMACEUTICALS, INC., a Delaware corporation having an address at 1896 Rutherford Road, Carlsbad, CA 92008 (“Isis”) and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, Cambridge, MA 02142 (together with its wholly owned subsidiaries Alnylam U.S., Inc., a Delaware corporation, and Alnylam Europe AG, a company organized under the laws of Germany, “Alnylam”). Isis and Alnylam may be referred to herein as the “Parties,” or each individually as a “Party.”
STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • May 8th, 2020 • Codexis, Inc. • Industrial organic chemicals • New York
This Strategic Collaboration and License Agreement (this “Agreement”) is made as of March 23, 2020 (the “Effective Date”), between Codexis, Inc., a Delaware corporation having its principal offices at 200 Penobscot Drive, Redwood City, California 94063 (“Codexis”) and Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited and a Delaware corporation having its principal offices at 300 Shire Way, Lexington, MA 02421 (“Takeda”). Codexis and Takeda may each be referred to herein individually as a “Party” or collectively, as the “Parties.”
SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • May 8th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Strategic Collaboration and License Agreement (the “Agreement”) is executed this January 8, 2015 (the “Second Restatement Date”), between Isis Pharmaceuticals, Inc., a Delaware corporation having an address at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (“Alnylam”). Isis and Alnylam may be referred to herein as the “Parties,” or each individually as a “Party.”
INNOVENT AND UNION THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION AND LICENSE AGREEMENT FOR ORISMILAST, A NEXT-GENERATION PDE4 INHIBITOR FOR INFLAMMATORYStrategic Collaboration and License Agreement • April 13th, 2019
This announcement is made by Innovent Biologics, Inc. (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. STRATEGIC COLLABORATION...Strategic Collaboration and License Agreement • November 7th, 2022 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of July 18, 2022 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of the Commonwealth of Massachusetts (“Vertex”) and Verve Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEENStrategic Collaboration and License Agreement • July 29th, 2019 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 6, 2019 (the “Execution Date”) by and between Vertex Pharmaceuticals Incorporated (“Vertex”) and CRISPR Therapeutics AG (“CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.”
STRATEGIC COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN HANSOH (SHANGHAI) HEALTHTECH CO., LTD. JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD. AND EQRX, INC. DATED AS OF JULY 22, 2020Strategic Collaboration and License Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • New York
THIS STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 22, 2020 (the “Effective Date”), by and among HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation incorporated under the laws of China having its principal place of business at Room 102, Block 1 No.298 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh Healthtech”) and JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD., a corporation incorporated under the laws of China having its principal place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyuangang, Jiangsu, China (“Jiangsu Hansoh” and together with Hansoh Healthtech, “Hansoh”), and EQRX, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02139, United States (“EQRx”). Hansoh and EQRx are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditionsStrategic Collaboration and License Agreement • September 27th, 2021
• Orismilast is a potential best-in-class PDE4 inhibitor in Phase 2 clinical development for the treatment of atopic dermatitis, psoriasis, and hidradenitis suppurativa
AMENDMENT NUMBER ONE TO THE SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • November 9th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE (the “Amendment”) to the Second Amended and Restated Strategic Collaboration and License Agreement is entered into as of the 13 day of July, 2015 (the “Amendment Effective Date”) by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”), and Isis Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Isis”).
Amendment No. 1 to the Strategic Collaboration and License AgreementStrategic Collaboration and License Agreement • April 27th, 2021 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Strategic Collaboration and License Agreement (the “Amendment”) is entered into as of March 17, 2021 (“Amendment Effective Date”) by and between Vertex Pharmaceuticals Incorporated (“Vertex”) and CRISPR Therapeutics AG (“CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Strategic Collaboration and License Agreement, entered into as of June 6, 2019, between Vertex and CRISPR, as supplemented (the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
AMENDMENT NUMBER ONE TO THE SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • November 9th, 2015 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE (the “Amendment”) to the Second Amended and Restated Strategic Collaboration and License Agreement is entered into as of the 13 day of July, 2015 (the “Amendment Effective Date”) by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”), and Isis Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Isis”).
STRATEGIC COLLABORATION AND LICENSE AGREEMENT AMONG ADAPTIMMUNE LIMITED,Strategic Collaboration and License Agreement • November 4th, 2021 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
This Strategic Collaboration and License Agreement (“Agreement”) is made and entered into, as of September 3, 2021 (“Execution Date”), by and among Adaptimmune Limited, having its principal place of business at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom (“Adaptimmune”), on the one hand, and Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080, United States (“GNE”), and F. Hoffmann-La Roche Ltd, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”), on the other hand. GNE and Adaptimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” The term “Party” or “Parties” shall not include Roche unless explicitly stated below.
AMENDMENT TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • November 3rd, 2017 • AntriaBio, Inc. • Pharmaceutical preparations
This AMENDMENT (the "Amendment") to the STRATEGIC COLLABORATION AND LICENSE AGREEMENT, dated February 29, 2016 (the "Agreement") is made and entered into as of October 31, 2017 ("Effective Date") by and between:
STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • April 28th, 2017 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of January 10, 2017 (the “Execution Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”), and Merck KGaA, a corporation with general partners under the laws of the Federal Republic of Germany, located at Frankfurter Strasse 250, 64293 Darmstadt Germany (“Merck”). Vertex and Merck each may be referred to herein individually as a “Party” or collectively as the “Parties.”
AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration and License Agreement • November 1st, 2023 • Entrada Therapeutics, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of October 26, 2023 (the “Amendment Effective Date”) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Vertex”), and, on the other hand, Entrada Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Strategic Collaboration and License Agreement, entered into as of December 7, 2022, between Vertex and Company (the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
STRATEGIC COLLABORATION AND LICENSE AGREEMENT by and between pH PHARMA Co., Ltd and ANTRIABIO, INC. Dated as of February 29, 2016Strategic Collaboration and License Agreement • March 2nd, 2016 • AntriaBio, Inc. • Pharmaceutical preparations • California
THIS STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of February 29, 2016 (“Effective Date”) by and between:
STRATEGIC COLLABORATION AND LICENSE AGREEMENT by and among VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED andStrategic Collaboration and License Agreement • August 4th, 2015 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of June 4, 2015 (“Effective Date”) by and among Parion Sciences, Inc., a corporation duly organized and validly existing under the laws of the state of Delaware (hereinafter referred to as “Parion”) and Vertex Pharmaceuticals Incorporated, a corporation duly organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and Vertex Pharmaceuticals (Europe) Limited, a private limited company organized under the laws of England and Wales (“Vertex UK” and, together with, Vertex Parent “Vertex”). Parion and Vertex are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
